NF-κB transcription factors function as crucial regulators of inflammatory and immune responses as well as of cell survival1. They have also been implicated in cellular transformation and tumorigenesis2,3,4,5,6. However, despite extensive biochemical characterization of NF-κB signalling during the past twenty years, the requirement for NF-κB in tumour development in vivo, particularly in solid tumours, is not completely understood. Here we show that the NF-κB pathway is required for the development of tumours in a mouse model of lung adenocarcinoma. Concomitant loss of p53 (also known as Trp53) and expression of oncogenic Kras(G12D) resulted in NF-κB activation in primary mouse embryonic fibroblasts. Conversely, in lung tumour cell lines expressing Kras(G12D) and lacking p53, p53 restoration led to NF-κB inhibition. Furthermore, the inhibition of NF-κB signalling induced apoptosis in p53-null lung cancer cell lines. Inhibition of the pathway in lung tumours in vivo, from the time of tumour initiation or after tumour progression, resulted in significantly reduced tumour development. Together, these results indicate a critical function for NF-κB signalling in lung tumour development and, further, that this requirement depends on p53 status. These findings also provide support for the development of NF-κB inhibitory drugs as targeted therapies for the treatment of patients with defined mutations in Kras and p53.
This is a preview of subscription content, access via your institution
Open Access articles citing this article.
Oncogene Open Access 23 February 2022
Molecular Biomedicine Open Access 17 December 2021
Signal Transduction and Targeted Therapy Open Access 15 November 2021
Subscribe to Journal
Get full journal access for 1 year
only $3.90 per issue
All prices are NET prices.
VAT will be added later in the checkout.
Tax calculation will be finalised during checkout.
Get time limited or full article access on ReadCube.
All prices are NET prices.
Hayden, M. S. & Ghosh, S. Signaling to NF-κB. Genes Dev. 18, 2195–2224 (2004)
Greten, F. R. et al. IKKβ links inflammation and tumorigenesis in a mouse model of colitis-associated cancer. Cell 118, 285–296 (2004)
Hanson, J. L., Hawke, N. A., Kashatus, D. & Baldwin, A. S. The nuclear factor κB subunits RelA/p65 and c-Rel potentiate but are not required for Ras-induced cellular transformation. Cancer Res. 64, 7248–7255 (2004)
Luedde, T. et al. Deletion of NEMO/IKKγ in liver parenchymal cells causes steatohepatitis and hepatocellular carcinoma. Cancer Cell 11, 119–132 (2007)
Maeda, S., Kamata, H., Luo, J. L., Leffert, H. & Karin, M. IKKβ couples hepatocyte death to cytokine-driven compensatory proliferation that promotes chemical hepatocarcinogenesis. Cell 121, 977–990 (2005)
Pikarsky, E. et al. NF-κB functions as a tumour promoter in inflammation-associated cancer. Nature 431, 461–466 (2004)
Herbst, R. S., Heymach, J. V. & Lippman, S. M. Lung cancer. N. Engl. J. Med. 359, 1367–1380 (2008)
Finco, T. S. et al. Oncogenic Ha-Ras-induced signaling activates NF-κB transcriptional activity, which is required for cellular transformation. J. Biol. Chem. 272, 24113–24116 (1997)
Huang, W. C., Ju, T. K., Hung, M. C. & Chen, C. C. Phosphorylation of CBP by IKKα promotes cell growth by switching the binding preference of CBP from p53 to NF-κB. Mol. Cell 26, 75–87 (2007)
Kawauchi, K., Araki, K., Tobiume, K. & Tanaka, N. p53 regulates glucose metabolism through an IKK-NF-κB pathway and inhibits cell transformation. Nature Cell Biol. 10, 611–618 (2008)
Kawauchi, K., Araki, K., Tobiume, K. & Tanaka, N. Loss of p53 enhances catalytic activity of IKKβ through O-linked β-N-acetyl glucosamine modification. Proc. Natl Acad. Sci. USA 106, 3431–3436 (2009)
Ravi, R. et al. p53-mediated repression of nuclear factor-κB RelA via the transcriptional integrator p300. Cancer Res. 58, 4531–4536 (1998)
Wadgaonkar, R. et al. CREB-binding protein is a nuclear integrator of nuclear factor-κB and p53 signaling. J. Biol. Chem. 274, 1879–1882 (1999)
Webster, G. A. & Perkins, N. D. Transcriptional cross talk between NF-κB and p53. Mol. Cell. Biol. 19, 3485–3495 (1999)
Jackson, E. L. et al. The differential effects of mutant p53 alleles on advanced murine lung cancer. Cancer Res. 65, 10280–10288 (2005)
Jackson, E. L. et al. Analysis of lung tumor initiation and progression using conditional expression of oncogenic K-ras. Genes Dev. 15, 3243–3248 (2001)
Jonkers, J. et al. Synergistic tumor suppressor activity of BRCA2 and p53 in a conditional mouse model for breast cancer. Nature Genet. 29, 418–425 (2001)
Johnson, L. et al. Somatic activation of the K-ras oncogene causes early onset lung cancer in mice. Nature 410, 1111–1116 (2001)
Ventura, A. et al. Restoration of p53 function leads to tumour regression in vivo . Nature 445, 661–665 (2007)
Rothwarf, D. M., Zandi, E., Natoli, G. & Karin, M. IKK-γ is an essential regulatory subunit of the IκB kinase complex. Nature 395, 297–300 (1998)
Yamaoka, S. et al. Complementation cloning of NEMO, a component of the IκB kinase complex essential for NF-κB activation. Cell 93, 1231–1240 (1998)
Ventura, A. et al. Cre-lox-regulated conditional RNA interference from transgenes. Proc. Natl Acad. Sci. USA 101, 10380–10385 (2004)
Perl, A.-K. T., Tichelaar, J. W. & Whitsett, J. A. Conditional gene expression in the respiratory epithelium of the mouse. Transgenic Res. 11, 21–29 (2002)
Nenci, A. et al. Epithelial NEMO links innate immunity to chronic intestinal inflammation. Nature 446, 557–561 (2007)
Stathopoulos, G. T. et al. Epithelial NF-κB activation promotes urethane-induced lung carcinogenesis. Proc. Natl Acad. Sci. USA 104, 18514–18519 (2007)
Fong, C. H. et al. An antiinflammatory role for IKKβ through the inhibition of “classical” macrophage activation. J. Exp. Med. 205, 1269–1276 (2008)
Hagemann, T. et al. “Re-educating” tumor-associated macrophages by targeting NF-κB. J. Exp. Med. 205, 1261–1268 (2008)
Pikarsky, E. & Ben-Neriah, Y. NF-κB inhibition: a double-edged sword in cancer? Eur. J. Cancer 42, 779–784 (2006)
DuPage, M., Dooley, A. L. & Jacks, T. Conditional mouse lung cancer models using adenoviral or lentiviral delivery of Cre recombinase. Nature Protocols 4, 1064–1072 (2009)
Schmittgen, T. D. & Livak, K. J. Analyzing real-time PCR data by the comparative C T method. Nature Protocols 3, 1101–1108 (2008)
We thank D. McFadden, T. Oliver, M. DuPage, K. Lane, A. Cheung, M. Kumar and E. Snyder for discussions and for sharing various reagents, A. Deconinck for critical reading of the manuscript, D. Crowley for preparation of tissue sections, and the entire Jacks laboratory for discussions. This work was supported by the Howard Hughes Medical Institute (T.J.) and partially by a Cancer Center Support grant from the NCI (P30-CA14051). T.J. is the David H. Koch Professor of Biology and a Daniel K. Ludwig Scholar. E.M. is a recipient of fellowships from the International Human Frontier Science Program Organization and the Swiss National Science Foundation. D.M.F. is a recipient of a Leukemia & Lymphoma Society Fellow Award.
Author Contributions E.M. and T.J. designed the study; E.M., A.L.D., L.S. and E.T. performed the experiments; D.M.F. generated the mouse lung cancer model with restorable p53; C.O. generated lung cell lines from tumours of these mice; E.M. and T.J. analysed the data; E.M. wrote the paper; and A.L.D. and T.J. edited the paper.
About this article
Cite this article
Meylan, E., Dooley, A., Feldser, D. et al. Requirement for NF-κB signalling in a mouse model of lung adenocarcinoma. Nature 462, 104–107 (2009). https://doi.org/10.1038/nature08462
Molecular Biomedicine (2021)
FKBP4 integrates FKBP4/Hsp90/IKK with FKBP4/Hsp70/RelA complex to promote lung adenocarcinoma progression via IKK/NF-κB signaling
Cell Death & Disease (2021)
Regulation of amyloid-β levels by matrix metalloproteinase-2/9 (MMP2/9) in the media of lung cancer cells
Scientific Reports (2021)
Signal Transduction and Targeted Therapy (2021)